United Therapeutics Corporation (UTHR) wird mit einem nachlaufenden KGV von gehandelt 19.2, erwartetes KGV von 19.7. Die nachlaufende Gewinnrendite beträgt 5.21%, erwartete Gewinnrendite 5.09%. PEG 1.46. Die Graham-Zahl beträgt $329.53.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 80/100 mit 5/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 8.8 | 0.59 | 3.37 | 3.93 | - |
| 2017 | 15.6 | -0.37 | 3.10 | 3.77 | - |
| 2018 | 8.0 | 0.19 | 1.70 | 2.91 | - |
| 2019 | -36.9 | 0.31 | 1.39 | 2.66 | - |
| 2020 | 13.0 | -0.02 | 1.98 | 4.52 | - |
| 2021 | 20.4 | -2.26 | 2.45 | 5.76 | - |
| 2022 | 17.4 | 0.34 | 2.64 | 6.53 | - |
| 2023 | 10.4 | 0.33 | 1.72 | 4.42 | - |
| 2024 | 13.3 | 0.52 | 2.47 | 5.54 | - |
| 2025 | 16.2 | 1.16 | 3.04 | 6.78 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $15.25 | $1.6B | $713.7M | 44.6% |
| 2017 | $9.31 | $1.73B | $417.9M | 24.2% |
| 2018 | $13.39 | $1.63B | $589.2M | 36.2% |
| 2019 | $-2.39 | $1.45B | $-104.5M | -7.2% |
| 2020 | $11.54 | $1.48B | $514.8M | 34.7% |
| 2021 | $10.06 | $1.69B | $475.8M | 28.2% |
| 2022 | $15.00 | $1.94B | $727.3M | 37.6% |
| 2023 | $19.81 | $2.33B | $984.8M | 42.3% |
| 2024 | $24.64 | $2.88B | $1.2B | 41.5% |
| 2025 | $27.86 | $3.18B | $1.33B | 41.9% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $29.23 | $27.20 – $31.10 | $3.31B | $3.19B – $3.41B | 11 |
| 2027 | $32.95 | $23.28 – $39.92 | $3.71B | $3.18B – $4.27B | 10 |
| 2028 | $38.67 | $27.47 – $49.97 | $4.26B | $4.19B – $4.32B | 10 |
| 2029 | $46.47 | $40.25 – $52.38 | $5.02B | $4.51B – $5.52B | 4 |
| 2030 | $53.13 | $46.02 – $59.88 | $5.79B | $5.19B – $6.35B | 4 |
